Artivion (NYSE:AORT) SVP Jean Holloway Sells 7,315 Shares

Artivion, Inc. (NYSE:AORT) SVP Jean Holloway sold 7,315 shares of Artivion stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $45.30, for a total value of $331,369.50. Following the completion of the transaction, the senior vice president directly owned 156,093 shares of the company’s stock, valued at approximately $7,071,012.90. This represents a 4.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Artivion Stock Down 0.7%

Shares of NYSE AORT traded down $0.30 during midday trading on Friday, hitting $45.11. 7,327 shares of the company’s stock were exchanged, compared to its average volume of 428,670. The firm’s fifty day simple moving average is $43.96 and its 200-day simple moving average is $38.00. The company has a debt-to-equity ratio of 0.50, a current ratio of 3.93 and a quick ratio of 2.88. The company has a market cap of $2.14 billion, a PE ratio of -187.96 and a beta of 1.60. Artivion, Inc. has a twelve month low of $21.97 and a twelve month high of $48.04.

Artivion (NYSE:AORT) last posted its earnings results on Thursday, November 6th. The company reported $0.16 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.02. The business had revenue of $113.39 million for the quarter, compared to analysts’ expectations of $110.71 million. Artivion had a positive return on equity of 5.98% and a negative net margin of 2.16%.The business’s revenue for the quarter was up 18.9% compared to the same quarter last year. Research analysts predict that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on AORT. Weiss Ratings restated a “sell (d-)” rating on shares of Artivion in a research note on Wednesday, October 8th. Needham & Company LLC upped their price target on Artivion from $50.00 to $58.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Canaccord Genuity Group boosted their price objective on shares of Artivion from $50.00 to $51.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Oppenheimer restated an “outperform” rating and issued a $50.00 price target on shares of Artivion in a research note on Friday, November 7th. Finally, Stifel Nicolaus raised their target price on Artivion from $40.00 to $46.00 and gave the company a “buy” rating in a report on Monday, September 29th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Artivion has a consensus rating of “Moderate Buy” and a consensus target price of $49.11.

Institutional Investors Weigh In On Artivion

Hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. raised its position in shares of Artivion by 8.3% in the 3rd quarter. Vanguard Group Inc. now owns 3,029,059 shares of the company’s stock valued at $128,250,000 after purchasing an additional 232,424 shares in the last quarter. Wellington Management Group LLP raised its stake in Artivion by 4.1% during the first quarter. Wellington Management Group LLP now owns 1,727,408 shares of the company’s stock worth $42,460,000 after acquiring an additional 67,327 shares during the period. Next Century Growth Investors LLC lifted its holdings in Artivion by 107.6% in the first quarter. Next Century Growth Investors LLC now owns 1,022,775 shares of the company’s stock worth $25,140,000 after acquiring an additional 530,122 shares during the last quarter. Bank of America Corp DE lifted its holdings in Artivion by 22.8% in the second quarter. Bank of America Corp DE now owns 645,070 shares of the company’s stock worth $20,062,000 after acquiring an additional 119,634 shares during the last quarter. Finally, Invesco Ltd. boosted its stake in Artivion by 40.8% in the second quarter. Invesco Ltd. now owns 481,026 shares of the company’s stock valued at $14,960,000 after acquiring an additional 139,370 shares during the period. Institutional investors and hedge funds own 86.37% of the company’s stock.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.